Cytori Therapeutics (PSTV) Earnings growth forecast for next year

Plus Therapeutics, Inc. (PSTV) is developing a targeted irradiation system by integrating navigation-guided drugs for brain surgery. The current assessment of the company's EPS growth for next year on the GURU.Markets terminal chart confirms this trajectory, where 40.00 reflects the metric's baseline. Patents for targeted isotope delivery provide a protective moat, while partnerships with oncology centers accelerate the market launch of radioligands.

Cytori Therapeutics (PSTV): Expected earnings per share trend next year from 07/04/2022 to 08/03/2026

Comprehensive metric breakdowns and analytics for Plus Therapeutics, Inc. (PSTV)

- share price and consensus valuation forecast:

Stock Price plustherapeutics.com|PSTV - Consensus Target

- market capitalization details:

Market Capitalization Plus Therapeutics|PSTV - Total Enterprise Value

- book capitalization indicators:

Net Assets per Single Share Plus Therapeutics|PSTV - Accounting Value of Company|Market Value to Book Value Ratio plustherapeutics.com|PSTV - Total Asset Value of Company

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

PSTV - Profit After Payment of Taxes|Projected Future Earnings Plus Therapeutics, Inc.|PSTV - Company Value to Net Income|Forward P/E Multiple Plus Therapeutics Inc|PSTV - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cytori Therapeutics|PSTV - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Plus Therapeutics|PSTV - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months plustherapeutics.com|PSTV - Earnings per share trend in current year|Earnings growth forecast for next year Plus Therapeutics, Inc.

- sales and revenue indicators:

PSTV - Company Total Revenue|Company Future Sales Volume Cytori Therapeutics|PSTV - P/S Multiple|Forward Price-to-Revenue Multiple Plus Therapeutics

Basic company analysis:PSTV, Cytori Therapeutics

The development of innovative targeted radiotherapy methods for complex tumors forms the long-term capitalization potential of Plus Therapeutics, Inc. (PSTV). This growth target for next year's net income per share visualizes average expert expectations regarding EPS dynamics amid tight monetary policy. Assessing the percentage change in future earnings allows investors to determine the business model's resilience to multiple compression and evaluate the overall investment attractiveness of the asset.

Competitor analysis

OLMA (olema.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Puma Biotechnology (PBYI)|Earnings growth forecast for next year GLSI|ZNTL - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year MacroGenics Corp MGNX|Expected earnings per share trend next year PCSA|Eagle Pharma - Earnings growth forecast for next year